Search for: "Matter of Sophia"
Results 181 - 200
of 313
Sort by Relevance
|
Sort by Date
1 Aug 2018, 6:40 am
The investment tribunal seized with the matter could make the actions of the EPO the subject matter of the arbitral proceedings because – by analogy with ECHR case law – it is arguable that the EPC Member State cannot evade its obligations under the IIA by having delegated the grant of patents to the EPO. [read post]
17 Jul 2018, 2:24 am
Until the matter is resolved by the Special Supreme Court, competent in case of contradictory findings of the Supreme Court, the issue will be in a limbo. [read post]
13 Jul 2018, 7:38 am
L’Oréal, who was not the only cosmetics producer whose use and registration of AFTER SUN found itself under attack from Laboratorios Genesse, decided to take the matter to court – to this date the only way to cancel a Spanish national trademark. [read post]
12 Jul 2018, 6:19 am
However there has not been a case where an allegedly infringing product or process was clearly outside the claims as a matter of “normal interpretation” (which appears according to subsequent rulings to mean “purposive construction”) but was an immaterial variant. [read post]
5 Jul 2018, 4:37 am
Whether this fame is true or not did not matter for the GC: it found that the general public with an average degree of attention would be inclined to purchase the goods at issue, thinking that it will find similar qualities, such as an image of improving sex life, owing to the transfer of positive associations projected by the image of the earlier mark. [read post]
28 Jun 2018, 2:45 am
Sara MoranFollowing its denial of Actavis’ claim for declarations of non-infringement in respect of Eli Lilly’s European Patent, the Court of Appeal ruled on a number of procedural matters arising from that judgment. [read post]
26 Jun 2018, 3:35 pm
’ Hardon’s case has been remitted by the ILOAT to the EPO ‘to enable a Disciplinary Committee, differently constituted, to consider the matter under Article 102 of the Service Regulations and for the President to make a fresh decision. [read post]
22 Jun 2018, 12:35 am
These are all matters for member states’ national laws. [read post]
20 Jun 2018, 4:12 am
Note that Meyerlustenberger Lachenal AG has been involved in this matter on behalf of Gilead) The Swiss dispute in a nutshell The Swiss litigation is about the validity of Gilead Sciences Inc. [read post]
8 Jun 2018, 9:37 am
The GC fully endorsed this and made it clear that the BoA had no competence to rule of its own motion on an issue that was not part of the subject matter of the appeal proceedings. [read post]
7 Jun 2018, 10:13 am
According to the study, the choice between an EU authority and the EPO is a matter of policy that is up to the legislature. [read post]
2 Jun 2018, 5:55 am
The Court of Appeal also considered and overturned the existing judicial guidance on granting permission to appeal in patent matters. [read post]
29 May 2018, 4:53 am
Matters considered by IPEC The following four matters were sequentially considered by IPEC: Whether ESL had infringed SUL’s SULETS mark under section 10(1) of the TMA, i.e., was an identical mark used in relation to identical goods and services. [read post]
16 May 2018, 2:32 am
However, the Government appears to want to consider the matter further. [read post]
14 May 2018, 6:18 pm
However, the Government appears to want to consider the matter further. [read post]
5 May 2018, 7:43 am
Sophia Brill returned to last Wednesday’s Supreme Court oral argument in Trump v. [read post]
26 Apr 2018, 10:51 am
My colleague Mike Gruber was kind enough to compile the following brief summary of the Federal Patent Court’s full decision on the Raltegravir (Isentress®) compulsory license matter. [read post]
26 Apr 2018, 8:54 am
With still no news from the BVerfG, save that amicus briefs were to be filed which would slow matters down further, there was still no rush, but the legislation was passed in December, bringing the Parliamentary stage to an end. [read post]
26 Apr 2018, 4:48 am
It is clear that the AG is of the opinion that the patent did not “specifically and precisely” identify emtricitabine for the purposes of Article 3(a) although, as the AG acknowledges, this is a matter for the national court to decide. [read post]
24 Apr 2018, 1:27 am
More from our authors: Mediation: Creating Value in International Intellectual Property Disputes by Théophile Margellos, Sophia Bonne, Gordon Humphreys, Sven Stürmann € The post The Dilemma with Clinical Trials and the Patent Law appeared first on Kluwer Patent Blog. [read post]
